ATE288923T1 - Cd4-gamma2- und cd4-igg2-chimären - Google Patents

Cd4-gamma2- und cd4-igg2-chimären

Info

Publication number
ATE288923T1
ATE288923T1 AT03012917T AT03012917T ATE288923T1 AT E288923 T1 ATE288923 T1 AT E288923T1 AT 03012917 T AT03012917 T AT 03012917T AT 03012917 T AT03012917 T AT 03012917T AT E288923 T1 ATE288923 T1 AT E288923T1
Authority
AT
Austria
Prior art keywords
igg2
gamma2
chimeras
provides
expression vector
Prior art date
Application number
AT03012917T
Other languages
English (en)
Inventor
Paul J Maddon
Gary A Beaudry
Original Assignee
Progenics Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Progenics Pharm Inc filed Critical Progenics Pharm Inc
Application granted granted Critical
Publication of ATE288923T1 publication Critical patent/ATE288923T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70514—CD4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6875—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody being a hybrid immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Control Of Driving Devices And Active Controlling Of Vehicle (AREA)
  • Regulating Braking Force (AREA)
  • Vehicle Body Suspensions (AREA)
  • Automatic Cycles, And Cycles In General (AREA)
  • Steering Control In Accordance With Driving Conditions (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AT03012917T 1991-02-08 1992-02-10 Cd4-gamma2- und cd4-igg2-chimären ATE288923T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US65368491A 1991-02-08 1991-02-08

Publications (1)

Publication Number Publication Date
ATE288923T1 true ATE288923T1 (de) 2005-02-15

Family

ID=24621912

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03012917T ATE288923T1 (de) 1991-02-08 1992-02-10 Cd4-gamma2- und cd4-igg2-chimären

Country Status (9)

Country Link
US (2) US6451313B1 (de)
EP (2) EP1340769B1 (de)
JP (1) JP3670276B2 (de)
AT (1) ATE288923T1 (de)
AU (1) AU660662B2 (de)
CA (1) CA2080226C (de)
DE (1) DE69233480T2 (de)
ES (1) ES2237727T3 (de)
WO (1) WO1992013947A1 (de)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2080226C (en) * 1991-02-08 2004-05-04 Gary A. Beaudry Cd4-gamma2 and cd4-igg2 chimeras
US7070991B2 (en) * 1991-02-08 2006-07-04 Progenics Pharmaceuticals, Inc. Cells expressing a CD4-IgG2 chimeric heterotetramer
EP0664710A4 (de) * 1992-08-07 1998-09-30 Progenics Pharm Inc IMMUNOKONJUGATE BESTEHEND AUS EINEM NICHT-PEPTIDYLEN TEIL UND EINEM CD4-GAMMA2- ODER CD4-IgG2 TEIL, UND VERWENDUNGEN DAVON.
US5817767A (en) * 1993-02-24 1998-10-06 Progenics Pharmaceuticals, Inc. Synergistic composition of CD4-based protein and anti-HIV-1 antibody, and methods of using same
EP0771326A4 (de) * 1994-07-13 2002-01-16 Progenics Pharm Inc Gegenstände zur entfernung von hiv-1 aus einer probe und verfahren zu ihrer verwendung
WO2003040311A2 (en) * 2001-10-25 2003-05-15 The Government Of The United States Of America As Represented By The Secretary Of Health And Human Services Efficient inhibition of hiv-1 viral entry through a novel fusion protein including of cd4
US20030211470A1 (en) * 2002-03-15 2003-11-13 Olson William C. CD4-IgG2-based salvage therapy of HIV-1 infection
WO2004084816A2 (en) * 2003-03-21 2004-10-07 Progenics Pharmaceuticals, Inc. IMPROVED CD4-IgG2 FORMULATIONS
US8110665B2 (en) 2003-11-13 2012-02-07 Hanmi Holdings Co., Ltd. Pharmaceutical composition comprising an immunoglobulin FC region as a carrier
WO2005047337A1 (en) * 2003-11-13 2005-05-26 Hanmi Pharmaceutical Co., Ltd. A pharmaceutical composition comprising an immunoglobulin fc region as a carrier
WO2005089805A2 (en) * 2004-03-15 2005-09-29 Nektar Therapeutics Al, Corporation Polymer-based compositions and conjugates of hiv entry inhibitors
KR100754667B1 (ko) 2005-04-08 2007-09-03 한미약품 주식회사 비펩타이드성 중합체로 개질된 면역글로불린 Ｆｃ 단편 및이를 포함하는 약제학적 조성물
EP2025762A3 (de) 2006-01-17 2009-09-30 Health Research Inc. Heteroduplex-Trackingassay
US20080051503A1 (en) * 2006-08-28 2008-02-28 The Goodyear Tire & Rubber Company Method of mixing fiber loaded compounds using a Y-mix cycle
TWI388570B (zh) 2008-07-23 2013-03-11 韓美科學有限公司 包含具有三個官能端的非肽醯聚合物的多肽複合物
JP2013514795A (ja) * 2009-12-22 2013-05-02 ノバルティス アーゲー 治療における使用のための四価ｃｄ４７抗体定常領域融合タンパク質
AR096891A1 (es) 2013-07-12 2016-02-03 Hanmi Pharm Ind Co Ltd Conjugado de monómero polipéptido biológicamente activo y conjugado de fragmento fc de inmunoglobulina, que muestra aclaramiento mediado por receptor reducido, y el método para la preparación del mismo
KR102132144B1 (ko) * 2014-06-04 2020-07-09 악셀레론 파마 인코포레이티드 폴리스타틴 폴리펩티드를 이용한 장애의 치료방법 및 치료를 위한 조성물
US10010498B2 (en) 2014-06-04 2018-07-03 Acceleron Pharma Inc. Methods for treatment of amyotrophic lateral sclerosis with follistatin fusion proteins
CN107636154A (zh) 2015-03-26 2018-01-26 阿塞勒隆制药公司 促滤泡素抑制素相关的融合蛋白及其用途

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4664911A (en) * 1983-06-21 1987-05-12 Board Of Regents, University Of Texas System Immunotoxin conjugates employing toxin B chain moieties
JP3134874B2 (ja) 1986-08-21 2001-02-13 ザ・トラステイーズ・オブ・コロンビア・ユニヴアーシテイ・イン・ザ・シテイ・オブ・ニユー・ヨーク Ｔ細胞表面タンパク質ｔ４をコードするｄｎａ並びにｔ４フラグメントのａｉｄｓ治療への使用
WO1989001940A1 (en) 1987-09-04 1989-03-09 Biogen, Inc. Dna sequences, recombinant dna molecules and processes for producing soluble t4 proteins
US5336603A (en) 1987-10-02 1994-08-09 Genentech, Inc. CD4 adheson variants
PT88641B (pt) 1987-10-02 1993-04-30 Genentech Inc Metodo para a preparacao de uma variante de adesao
IL87902A0 (en) 1987-10-08 1989-03-31 Dana Farber Cancer Inst Inc Soluble human cd4 fragments and applications thereof
PT89484B (pt) * 1988-01-22 1994-03-31 Gen Hospital Corp Genes clonados codificadores de proteinas de fusao ig-cd4 e sua utilizacao
IL91070A (en) * 1988-07-23 1995-03-30 Us Commerce Cytotoxic agents against certain viral infections
JPH02107393A (ja) * 1988-10-18 1990-04-19 Asahi Chem Ind Co Ltd 排水中の塩素系溶剤の除去方法
US5116964A (en) 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
EP0394827A1 (de) * 1989-04-26 1990-10-31 F. Hoffmann-La Roche Ag Chimärische CD4-Immunoglobulin-Polypeptide
EP0479909B1 (de) * 1989-06-29 1996-10-30 Medarex, Inc. Bispezifische reagenzien für die aids-therapie
CA2080226C (en) * 1991-02-08 2004-05-04 Gary A. Beaudry Cd4-gamma2 and cd4-igg2 chimeras
AU1438592A (en) * 1991-02-08 1992-09-07 Progenics Pharmaceuticals, Inc. Cd4-gamma1 and cd4-igg1 chimeras
AU1423792A (en) * 1991-02-12 1992-09-07 Colorado State University Research Foundation Reagents and methods for identification of vaccines
EP0664710A4 (de) * 1992-08-07 1998-09-30 Progenics Pharm Inc IMMUNOKONJUGATE BESTEHEND AUS EINEM NICHT-PEPTIDYLEN TEIL UND EINEM CD4-GAMMA2- ODER CD4-IgG2 TEIL, UND VERWENDUNGEN DAVON.

Also Published As

Publication number Publication date
DE69233480D1 (de) 2005-03-17
EP0528011A4 (en) 1993-06-30
CA2080226C (en) 2004-05-04
ES2237727T3 (es) 2005-08-01
EP1340769A1 (de) 2003-09-03
EP1340769B1 (de) 2005-02-09
JPH05507854A (ja) 1993-11-11
CA2080226A1 (en) 1992-08-09
US6451313B1 (en) 2002-09-17
AU660662B2 (en) 1995-07-06
HK1059789A1 (en) 2004-07-16
JP3670276B2 (ja) 2005-07-13
DE69233480T2 (de) 2006-01-05
AU1440092A (en) 1992-09-07
EP0528011A1 (de) 1993-02-24
US6187748B1 (en) 2001-02-13
WO1992013947A1 (en) 1992-08-20

Similar Documents

Publication Publication Date Title
EP0528011A4 (en) Cd4-gamma2 and cd4-igg2 chimeras
ID30373A (id) PARAHERKUAMIDA ANTIPARASIT (Pecahan P-962086)
FI960631A0 (fi) Termostabiilit ksylanaasit
DE69205388D1 (de) Oberflächenemittierender Laser.
ID21924A (id) Olanzapin dihidrat d
EP0632550A3 (de) Modulation von Laserdioden.
DE3588044D1 (de) Kette mit gleichen Gliedern.
FR2718585B1 (fr) Modulateur avec codage amélioré.
DE69203784D1 (de) Gewinngekoppelter Halbleiterlaser mit verteilter Rückkoppelung.
DE69203169D1 (de) Konstantstromquelle.
DE69110605D1 (de) Halbleiterlaser mit verteilter Rückkoppelung.
DE68913046D1 (de) Laserbeständige beatmungsvorrichtung mit verbindungsmuffe.
DE69205399D1 (de) Spannungsverformte Quantumwell-Laserdiode.
DE68922166D1 (de) Chiffrierverfahren mit nachträglicher Quellenkodierung.
FI940893A7 (fi) N-asetyyliglukosaminyylitransferaasia V koodaavat sekvenssit
DE69400656D1 (de) Integrierte Lichtquelle mit Multiquantumwell-Diodenlaser/Modulator
DK0387894T3 (da) Kædeforlængere for 4,4-diisocyanato-diphenylmethan-præpolymere for støbte polyurethan-elastomere (PU-elastomere)
EP0650112A3 (de) Konstantstromquelle.
ATE81131T1 (de) N-silyl-substituierte 1-sila-2-azacyclopentane.
FR2701574B1 (fr) Modulateur semi-conducteur d'intensité de lumière.
DE69200569D1 (de) Binäre Modulation von Injektionslasern.
EP0617491A3 (de) Lichtemittierendes Halbleiterbauelement.
DE3871337D1 (de) Kettenglied mit schmelzelement.
FI883714A0 (fi) Stabilisatorer foer elektrostatiska, flytande framkallare.
DE69304095D1 (de) Laserdiode mit verteilter Rückkopplung mit selektiv angeordneten Verlustabschnitten

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1340769

Country of ref document: EP

REN Ceased due to non-payment of the annual fee